FDA Inspection 1280973 — Polypeptide Laboratories France
The FDA completed an inspection of Polypeptide Laboratories France on July 4, 2024 in Strasbourg. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions were found but do not meet the threshold for regulatory action). Product area: Drugs.
Inspection Details
- Classification
- Voluntary Action Indicated (VAI) (VAI)
- End Date
- July 4, 2024
- Fiscal Year
- 2024
- Product Type
- Drugs
- Project Area
- Drug Quality Assurance
- Location
- Strasbourg (France)
Additional Details
Mutual Recognition Agreement (MRA)